Skip to content

OPIANT PHARMACEUTICALS, INC.

CIK 0001385508

← back to feed
Revenue (TTM)
$24.88M
+61.3% YoY Q3 Nov 2022
Net Income (TTM)
−$30.42M
+261.6% YoY Q3 Nov 2022
EPS Diluted (TTM)
−$6.11
+215.9% YoY Q3 Nov 2022
Gross Margin
100.0%
Q3 Nov 2022
Operating Margin
-115.9%
Q3 Nov 2022
Net Margin
-122.3%
Q3 Nov 2022
Free Cash Flow (TTM)
−$1.01M
Q3 Nov 2022
Cash
$35.38M
Q3 Nov 2022
Total Debt
$12.32M
Q3 Nov 2022
Shares Outstanding
5.17M sh
Q3 Nov 2022

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings